Skip to content

Enterprise value at other companies

IAR
Integra LifeSciencesIART
$2.47B-26.7%
MiMedx Group logo
MiMedx GroupMDXG
$444.66M-56.9%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
$577.67M-23.8%
Bioventus logo
BioventusBVS
$867.64M-8.5%
Artivion logo
ArtivionAORT
$1.96B+44.0%
Axogen logo
AxogenAXGN
$1.66B+91.4%

Other financials

Income statement

See full
Revenue$37.2M-57.1%
Gross profit$63.0M-22.5%
Operating income-$68.9M-158%
Net income-$53.2M-182%
EPS (diluted)-$0.44-159%

Balance sheet

See full
Cash & equivalents$91.4M-16.9%
Total debt$39.4M+24.8%
Total equity$244.6M+0.7%
Total assets$520.0M+11.3%

Cash flow

See full
Operating cash flow$21.1M+206%
CapEx$3.1M-13.2%
Free cash flow$18.0M+176%

Valuation

See full
Market cap$312.68M-23.7%
P/E115×
P/S0.6×-0.3×

Profitability

See full
Gross margin75.9%+0.8pp
Operating margin0.5%
Net margin0.5%+0.3pp
FCF margin6.9%

Returns & leverage

See full
Return on equity1.1%+0.6pp
Debt / equity0.2×0.0×
Current ratio3.5×-0.6×

Where this comes from

Calculated from Organogenesis Holdings Inc.’s reported figures.

The official record: Organogenesis Holdings Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organogenesis Holdings Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organogenesis Holdings Inc.'s enterprise value?
Organogenesis Holdings Inc. (ORGO) reported enterprise value of $252.92M in Q1 2026.
How has Organogenesis Holdings Inc.'s enterprise value changed year-over-year?
Organogenesis Holdings Inc.'s enterprise value decreased by 46.1% year-over-year, from $469.51M to $252.92M.
What is the long-term trend for Organogenesis Holdings Inc.'s enterprise value?
Over 5 years (2020 to 2025), Organogenesis Holdings Inc.'s enterprise value has grown at a -7.3% compound annual growth rate (CAGR), from $956.13M to $655.3M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.